Pacific Biosciences Of California (PACB) Assets Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.56% |
| Dec 31, 2025 | -23.73% |
| Sep 30, 2025 | -23.85% |
| Jun 30, 2025 | -23.94% |
| Mar 31, 2025 | -23.68% |
| Dec 31, 2024 | -14.36% |
| Jun 30, 2024 | 6.61% |
| Mar 31, 2024 | 10.05% |
| Dec 31, 2023 | 61.57% |
| Sep 30, 2023 | 84.90% |
| Jun 30, 2023 | 105.26% |
| Mar 31, 2023 | 100.65% |
| Dec 31, 2022 | 128.57% |
| Sep 30, 2022 | 131.76% |
| Jun 30, 2022 | 122.39% |
| Mar 31, 2022 | 118.53% |
| Dec 31, 2021 | 127.58% |
| Jun 30, 2021 | 108.70% |
| Mar 31, 2021 | 99.86% |
| Dec 31, 2020 | 42.16% |
| Sep 30, 2020 | 23.90% |
| Jun 30, 2020 | 6.29% |
| Mar 31, 2020 | 20.10% |
| Dec 31, 2019 | 2.38% |
| Sep 30, 2019 | -1.01% |
| Jun 30, 2019 | 1.87% |
| Mar 31, 2019 | 9.80% |
| Dec 31, 2018 | 9.10% |
| Sep 30, 2018 | 22.39% |
| Jun 30, 2018 | 12.30% |
| Mar 31, 2018 | 13.83% |
| Dec 31, 2017 | 5.02% |
| Sep 30, 2017 | 9.09% |
| Jun 30, 2017 | 11.53% |
| Mar 31, 2017 | -1.32% |
| Dec 31, 2016 | 0.41% |
| Sep 30, 2016 | -0.47% |
| Jun 30, 2016 | 6.32% |
| Dec 31, 2015 | 0.36% |
| Mar 31, 2015 | -18.24% |
| Dec 31, 2014 | -17.10% |
| Sep 30, 2014 | -20.04% |
| Jun 30, 2014 | -21.11% |
| Dec 31, 2013 | -23.63% |